Calidi Biotherapeutics Inc. reported its first quarter 2025 financial results, showing a net loss attributable to common stockholders of $5.0 million, or $0.18 per share, for the three months ended March 31, 2025. This represents a decrease in net loss from the same period in 2024, which was $7.2 million, or $2.03 per share. Research and development expenses for the quarter were $2.4 million, down from $2.7 million in the comparable period in 2024. General and administrative expenses also saw a reduction, totaling $2.6 million for the first quarter of 2025, compared to $4.0 million for the same period in 2024. Calidi Biotherapeutics ended the quarter with approximately $10.6 million in cash and $0.2 million in restricted cash, an increase from $9.6 million in cash and $0.2 million in restricted cash as of December 31, 2024. In terms of operational highlights, Calidi has strengthened its management team with the appointment of a new Chief Executive Officer, Eric Poma, PhD, and a Chief Medical Officer. Additionally, the company announced the selection of an IL15-superagonist as the first payload to be delivered into tumors with its lead candidate using the systemic antitumor virotherapy platform, Redtail. An IND filing for this candidate is expected in the second half of 2026. Furthermore, the IND for the CLD-201 clinical trial has been cleared by the FDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.